Robert Preti - Caladrius Biosciences Director
| CLBSDelisted Stock | USD 0.43 0.39 895.37% |
Director
Dr. Robert A. Preti Ph.D. is Chairman of the Alliance for Regenerative Medicine Director of the Company. He serves as President and Chief Scientific Officer PCT of NeoStem Inc. Dr. Preti serves as President of PCT. Dr. Preti also serves as Chief Scientific Officer of PCT. Prior to our acquisition of PCT Dr. Preti had served from 1999 to 2011 as President and Chief Scientific Officer for PCT and as a member of PCT Board of Managers. Dr. Preti was Scientific Director of Hackensack University Medical Center stem cell laboratory from 1996 1999. Prior to that he served as director at the Clinical Services Division of the New York Blood Center from 1989 to 1996. He is one of the country leading authorities on cell engineering and the principal investigator for a number of clinical trials relating to stem cell transplantation. He was a founding member and Treasurer of the International Society for Hematotherapy and Graft Engineering and served for 10 years on its Executive Committee and Board of Directors. He is now representing Cellular Therapy as a Director of the American Association of Blood Banks. Dr. Preti has authored numerous papers in the field and was invited to speak at national and international meetings relating to the manufacturing regulatory and quality aspects of cell therapy and regenerative medicine. In addition to having served as an inspector for the Foundation for Accreditation of Cellular Therapy Dr. Preti also serves on professional and state committees charged with the development of regulations for cellular therapy since 2016.
| Age | 58 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 908 842-0100 |
| Web | www.caladrius.com |
Caladrius Biosciences Management Efficiency
The company has return on total asset (ROA) of (16.73) % which means that it has lost $16.73 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (23.84) %, meaning that it generated substantial loss on money invested by shareholders. Caladrius Biosciences' management efficiency ratios could be used to measure how well Caladrius Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 626 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Caladrius Biosciences has a current ratio of 31.73, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Caladrius Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Caladrius Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Caladrius Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Caladrius to invest in growth at high rates of return. When we think about Caladrius Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Anna Manz | Diageo PLC ADR | 42 | |
| Betsy Holden | Diageo PLC ADR | 63 | |
| Daniel Mobley | Diageo PLC ADR | 40 | |
| Siobhan Moriarty | Diageo PLC ADR | 54 | |
| Nabil Sakkab | Altria Group | 74 | |
| Leo Kiely | Altria Group | 68 | |
| Roberto Monti | Tenaris SA ADR | 79 | |
| Carlos Condorelli | Tenaris SA ADR | 68 | |
| Simon Ayat | Tenaris SA ADR | 65 | |
| III Casteen | Altria Group | 74 | |
| Valerie ChapoulaudFloquet | Diageo PLC ADR | 58 | |
| Susan Kilsby | Diageo PLC ADR | 62 | |
| Carlos Franck | Tenaris SA ADR | 64 | |
| Thomas Jones | Altria Group | 65 | |
| Jose Mas | Helmerich and Payne | 49 | |
| Debra KellyEnnis | Altria Group | 64 | |
| Jose Mackenna | Compania Cervecerias Unidas | 63 | |
| Ireena Vittal | Diageo PLC ADR | 51 | |
| Charlotte Lambkin | Diageo PLC ADR | 43 | |
| Donald Robillard | Helmerich and Payne | 69 | |
| John Simpson | Awilco Drilling PLC | 66 | |
Management Performance
| Return On Equity | -23.84 | |||
| Return On Asset | -16.73 |
Caladrius Biosciences Leadership Team
Elected by the shareholders, the Caladrius Biosciences' board of directors comprises two types of representatives: Caladrius Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Caladrius. The board's role is to monitor Caladrius Biosciences' management team and ensure that shareholders' interests are well served. Caladrius Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Caladrius Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Mazzo, CEO, Director | ||
| Catherine Vaczy, Vice President | ||
| Robert Preti, CTO, Sr. VP of Manufacturing and Technical Operations and Director | ||
| Eric Wei, Director | ||
| Richard Berman, Independent Director | ||
| Steven Myers, Independent Director | ||
| Cynthia Schwalm, Director | ||
| Todd Girolamo, General Counsel | ||
| Gregory Brown, Director | ||
| Steven Klosk, Independent Director | ||
| Douglas Losordo, Chief Medical Officer | ||
| Martyn Greenacre, Independent Director | ||
| Joseph Talamo, CFO and Sr. VP | ||
| Andrew Pecora, Chief Visionary Officer, Director | ||
| Peter Traber, Independent Director | ||
| Drew Bernstein, Independent Director |
Caladrius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Caladrius Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -23.84 | |||
| Return On Asset | -16.73 | |||
| Current Valuation | (57.88 M) | |||
| Shares Outstanding | 59.78 M | |||
| Shares Owned By Insiders | 2.74 % | |||
| Shares Owned By Institutions | 18.51 % | |||
| Number Of Shares Shorted | 543.94 K | |||
| Price To Earning | (0.28) X | |||
| Price To Book | 0.25 X | |||
| Price To Sales | 1.00 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Caladrius Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Caladrius Biosciences' short interest history, or implied volatility extrapolated from Caladrius Biosciences options trading.
Pair Trading with Caladrius Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Caladrius Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Caladrius Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving against Caladrius Stock
| 0.42 | MRNA | Moderna Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Caladrius Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Caladrius Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Caladrius Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Caladrius Biosciences to buy it.
The correlation of Caladrius Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Caladrius Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Caladrius Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Caladrius Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Caladrius Biosciences information on this page should be used as a complementary analysis to other Caladrius Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Caladrius Stock
If you are still planning to invest in Caladrius Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Caladrius Biosciences' history and understand the potential risks before investing.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |